Jubilant Pharmova Ltd Share Price & Stock Analysis

Jubilant Pharmova Ltd (BSE: 530019) is a Noida, Uttar Pradesh-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹15,556 Cr, it ranks #451 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 11 in Pharmaceutical CDMO and CRO Services. At ₹964.65 (as of 16 Nov 2026), the share price is 17.0% below its 52-week high of ₹1,162.00 and 22.7% above its 52-week low of ₹786.05. The share price is down 14.5% over one year and up 8.3% over three months.

Key Metrics

Current Price₹964.65
Market Cap₹15,556 Cr
BSE Code530019
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services > Pharmaceutical CDMO and CRO Services
P/E Ratio39.1
Return on Equity5.96%
Return on Assets3.62%
52-Week Range₹786.05 – ₹1,162.00
1-Year Price Change-14.5%
3-Month Price Change+8.3%
Beta (1Y)0.29
Dividend Yield0.51%
HeadquartersNoida, Uttar Pradesh
Websitewww.jubilantpharmova.com

Latest Quarterly Results — Q2 FY27

Revenue₹2,370 Cr
Net Profit₹31 Cr
Net Margin1.3%
EPS (Basic)₹1.97
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Jubilant Pharmova Ltd Quarterly Revenue and Profit Trend

Jubilant Pharmova Ltd reported revenue of ₹2,370 Cr in Q2 FY27, up 20.5% from ₹1,966 Cr in Q2 FY26 and up 6.3% from ₹2,229 Cr in Q1 FY27. It posted a net profit of ₹31 Cr for the quarter, against a net profit of ₹120 Cr in Q2 FY26 (down 74.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,901 Cr (Q1 FY26) to ₹2,370 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹2,370 Cr₹31 Cr1.3%
Q1 FY27₹2,229 Cr₹56 Cr2.5%
Q4 FY26₹2,290 Cr₹119 Cr5.2%
Q3 FY26₹2,123 Cr₹56 Cr2.6%
Q2 FY26₹1,966 Cr₹120 Cr6.1%
Q1 FY26₹1,901 Cr₹103 Cr5.4%
Q4 FY25₹1,929 Cr₹151 Cr7.8%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 47.68% of Jubilant Pharmova Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 43.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Jubilant Pharmova Ltd

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distr

Products and Services

1. Pharmaceuticals (Excluding Drug Discovery and Development Solutions)-This segment offers specialty pharmaceuticals, including radiopharmaceuticals and allergy therapy products; contract development and manufacturing services; generics, such as solid dosage formulations; and India branded pharmaceuticals. 2. Contract Research and Development Services (Excl. Proprietary Novel Drugs)-This segment offers drug discovery and development services, as well as clinical data software and service solutions. 3. Proprietary Novel Drugs-This segment offers biopharmaceutical products to address oncology and autoimmune diseases. 4. Inter-Segment Revenue-0

Business Segments

1. Radio Pharma-44.6% 2. Allergy Immunotherapy-9.6% 3. Contract Development and Manufacturing Organization - Sterile Injectables-21.9% 4. Contract Research, Development and Manufacturing Organization-15.3% 5. Generics-9.3% 7. Unallocable Corporate-0.7%

Jubilant Pharmova Ltd vs Peers — Pharmaceutical CDMO and CRO Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Divis Laboratories Limited₹3,01,758 Cr118.416.19%₹3,676 Cr+71.9%
Anthem Biosciences Limited₹53,926 Cr90.119.45%₹594 Cr+34.5%
Sai Life Sciences Limited₹40,755 Cr116.115.13%₹659 Cr+120.3%
Onesource Specialty Pharma Limited₹18,138 Crn/m-1.26%₹516 Cr-9.4%
Cohance Lifesciences Ltd₹17,756 Cr100.65.11%₹477 Cr-35.2%
Syngene International Ltd.₹17,630 Cr56.96.62%₹833 Cr-27.9%
Jubilant Pharmova Ltd₹15,556 Cr39.15.96%₹2,370 Cr-14.5%
Concord Biotech Ltd₹12,495 Cr24.213.54%₹309 Cr-14.8%
Blue Jet Healthcare Ltd₹10,140 Cr3819.88%₹376 Cr-9.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Jubilant Pharmova Ltd?

Jubilant Pharmova Ltd is trading at ₹964.65, with a market capitalisation of ₹15,556 Cr.

Which sector does Jubilant Pharmova Ltd belong to?

Jubilant Pharmova Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).

What are the key financial ratios of Jubilant Pharmova Ltd?

Jubilant Pharmova Ltd has a P/E of 39.1 and a return on equity of 5.96%.

What is the stock symbol of Jubilant Pharmova Ltd?

Jubilant Pharmova Ltd is listed on the BSE under the scrip code 530019.

How has Jubilant Pharmova Ltd's share price moved over the past year?

Jubilant Pharmova Ltd's share price is down 14.5% over one year and up 8.3% over three months. Its 52-week range is ₹786.05 to ₹1,162.00.

What were Jubilant Pharmova Ltd's latest quarterly results?

In Q2 FY27, Jubilant Pharmova Ltd reported revenue of ₹2,370 Cr and net profit of ₹31 Cr, with basic EPS of ₹1.97 (consolidated, parsed from the company's exchange filing).

How have Jubilant Pharmova Ltd's revenue and profit changed over the past year?

Jubilant Pharmova Ltd reported revenue of ₹2,370 Cr in Q2 FY27, up 20.5% from ₹1,966 Cr in Q2 FY26 and up 6.3% from ₹2,229 Cr in Q1 FY27.

What is the promoter holding in Jubilant Pharmova Ltd?

Promoters held 47.68% of Jubilant Pharmova Ltd's shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.